Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| hormone refractory prostate |
|
Prostate Cancer Basics - About Hormone Refractory Prostate Cancer The following is a list of questions to ask your doctor About Hormone Refractory Prostate Cancer as well as tips for preparing for these conversations. IngentaConnect Satraplatin in Hormone-Refractory Prostate Cancer Oral satraplatin plus prednisone improved progression free survival significantly relative to prednisone alone in patients with hormone-refractory prostate Loss of mir-146a function in hormone-refractory prostate cancer These identified miRNAs showed the same expression patterns in hormone-refractory prostate carcinomas (HRPC) compared to androgen-sensitive noncancerous IngentaConnect Management Strategies for Hormone-Refractory The combination of docetaxel with prednisone has a clear role in patients with symptomatic hormone-refractory prostate cancer; however, Metastatic And Hormone Refractory Prostate cancer Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies Satraplatin Curbs Hormone-Refractory Prostate Cancer Combination treatment with satraplatin and prednisone appears to increase progression-free survival in patients with hormone-refractory prostate cancer Molecular Features of Hormone-Refractory Prostate Cancer Cells by One of the most critical issues in prostate cancer clinic is emerging hormone-refractory prostate cancers (HRPCs) and their management. Immunotherapy of hormone-refractory prostate cancer with antigen PATIENTS AND METHODS: All patients had hormone-refractory prostate cancer. Dendritic-cell precursors were harvested by leukapheresis in weeks 0, 4, 8, Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer | Strategic Report | BUY NOW from Piribo.com - á¸8000 / $16114 / Á‚¬11789 - Currently Taxanes in Hormone-Refractory Prostate Cancer docetaxel in patients with hormone refractory prostate can-. cer. Proc ASCO. 1999;18:1239. the treatment of hormone-refractory prostate cancer. Semin ijcp_1551 2064..2070 hormone-refractory prostate cancer (HRPC) to provide recommendations for the .. 182751) given daily á· 5 in hormone refractory prostate cancer. (HRPC). Chemotherapy for hormone-refractory prostate cancer Mike Shelley, Craig Harrison, Bernadette Coles, John Staffurth, Timothy J Wilt, Malcolm D Mason. Chemotherapy for hormone-refractory prostate cancer. Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Cleveland BioLabs, Inc. (Nasdaq: CBLI; BSE: CFB), announced today that its Phase II efficacy study for Curaxin CBLC102 in advanced, hormone-refractory Cleveland BioLabs Initiates Phase II Hormone-Refractory Prostate Cleveland BioLabs, Inc. (Nasdaq: CBLI)(BSE: CFB), announced today the initiation of its Phase II efficacy study for Curaxin CBLC102 in advanced, Hormone-refractory prostate cancer - Hutchinson encyclopedia Hutchinson encyclopedia article about Hormone-refractory prostate cancer. Hormone-refractory prostate cancer. Information about Hormone-refractory prostate Management of hormone-refractory prostate cancer, from the Management of hormone-refractory prostate cancer, from Prostate Cancer Infolink web site, preserved at Phoenix5. Prostate cancer (hormone-refractory) - docetaxel Docetaxel for the treatment of hormone refractory prostate cancer TA101 Prostate cancer (hormone-refractory) - docetaxel: analysis of cost impact Hormone-Refractory Prostate Cancer with Bone Metastases - Prostate Newer Concepts in the Treatment of Hormone-Refractory Prostate Cancer with Bone Metastases: Combinations of Bone-Seeking Radiopharmaceuticals and Hormone Refractory Prostate Cancer - hrpca.org For those men facing hormone refractory prostate cancer. This is a support group for HRPC issues only. |
| hormone refractory prostate |
|
lateral lobes of prostate male prostate milking prostate cancer gleason score treatment lower back pain prostate |